Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer
Kite, a Gilead Company (Nasdaq: GILD), and Appia Bio, Inc., an early stage biotechnology company developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients, today announced a collaboration and license agreement to research and develop HSC-derived cell therapies directed toward hematological malignancies.
- Kite, a Gilead Company (Nasdaq: GILD), and Appia Bio, Inc., an early stage biotechnology company developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients, today announced a collaboration and license agreement to research and develop HSC-derived cell therapies directed toward hematological malignancies.
- Under the partnership, Kite and Appia Bio will develop chimeric antigen receptor (CAR)-engineered invariant natural killer T (CAR-iNKT) cells using Appia Bios ACUA technology platform for allogeneic cell therapy.
- With its ACUA technology platform, Appia Bio leverages the biology of lymphocyte development to generate CAR-iNKT cells from HSCs.
- Through our collaboration with Appia Bio, were excited to harness unique biological properties of invariant natural killer T cells to research and develop allogeneic cell therapies for cancer.